MPM Asset Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-4,050,865
| Closed | -$6.08M | – | 9 |
|
|
2023
Q1 | $6.08M | Hold |
4,050,865
| – | – | 2.53% | 7 |
|
|
2022
Q4 | $4.05M | Hold |
4,050,865
| – | – | 1.69% | 7 |
|
|
2022
Q3 | $7.29M | Hold |
4,050,865
| – | – | 2.78% | 7 |
|
|
2022
Q2 | $11.7M | Hold |
4,050,865
| – | – | 4.96% | 7 |
|
|
2022
Q1 | $11.2M | Hold |
4,050,865
| – | – | 3.82% | 8 |
|
|
2021
Q4 | $18.9M | Hold |
4,050,865
| – | – | 4.08% | 8 |
|
|
2021
Q3 | $34.5M | Hold |
4,050,865
| – | – | 7.99% | 5 |
|
|
2021
Q2 | $66.5M | Hold |
4,050,865
| – | – | 12.36% | 5 |
|
|
2021
Q1 | $89.4M | Hold |
4,050,865
| – | – | 17.28% | 2 |
|
|
2020
Q4 | $125M | Hold |
4,050,865
| – | – | 17.73% | 2 |
|
|
2020
Q3 | $82.3M | Hold |
4,050,865
| – | – | 15.35% | 4 |
|
|
2020
Q2 | $62.2M | Hold |
4,050,865
| – | – | 18.51% | 3 |
|
|
2020
Q1 | $31.4M | Hold |
4,050,865
| – | – | 19.07% | 3 |
|
|
2019
Q4 | $57.8M | Hold |
4,050,865
| – | – | 25.46% | 2 |
|
|
2019
Q3 | $60.9M | Hold |
4,050,865
| – | – | 26.06% | 3 |
|
|
2019
Q2 | $58M | Hold |
4,050,865
| – | – | 23.42% | 3 |
|
|
2019
Q1 | $70.6M | Buy |
+4,050,865
| New | +$71.8M | 29.11% | 2 |
|
MPM Asset Management's TCRR Position: Q2 2023 in Review
MPM Asset Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 4,050,865 shares — an estimated $6.08M sold.
MPM Asset Management first reported a position in TCRR in Q1 2019 and held it in 17 quarters. The position peaked at $125M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- MPM Asset Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- MPM Asset Management sold 4,050,865 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $6.08M.
- MPM Asset Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 17 quarters.
- MPM Asset Management's TCR2 Therapeutics Inc. Common Stock position peaked at $125M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on MPM Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.